Updates on Immunotherapy of Cancer and Immunoscore

Part of the Sidra Symposia Series, Held in Partnership with the Society for Immunotherapy of Cancer

January 22-23, 2014
Four Seasons Hotel
Doha, Qatar

View presentation slides from this program as well as meeting abstracts published in JITC.

Program Purpose

This symposium provided an educational environment focused on improving the outcome for patients with cancer by incorporating strategies based on cancer immunotherapy. With leading authorities in tumor immunology and cancer immunotherapy, as well as oral abstract and poster presenters, this program described the latest research advances, focused on currently approved and emerging tumor immunotherapy approaches, provided highlights on SITC initiatives and projects, and offered updates on international initiatives, including the Immunoscore.

Intended Audience

The target audience for this program was basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research that wish to learn more about advances in cancer immunology and immunotherapy.

Topics

*denotes non-abstract category

• Cell Therapy of Cancer
• Checkpoint Blockade
• Combination Therapies
• Highlights of the Annual Meeting for the Society of Immunotherapy of Cancer*
• Highlights of the Workshop on Personalized Immunotherapy of Cancer*
• Immune Surveillance of Cancer
• Immunomodulation in Cancer with Special Reference to Regulatory T cells and B7-H1
• Immunoscore*
• Obesity, Inflammation and Cancer
• Regulatory Hurdles*
• Role of Inflammation in Cancer
• Therapeutic Cancer Vaccines
• Tumor Microenvironment

Program Goals

Updates on Immunotherapy of Cancer and Immunoscore provided  the opportunity to:

• Contrast the efficacy and adaptability of distinct immunotherapeutic strategies and pursue opportunities for integrating them
• Identify global cancer immunotherapy initiatives and assess their impact on and growth in local practice
• Investigate how to integrate immunotherapeutic approaches for cancer treatment into current conventional regimens to increase clinical benefit
• Share data and ideas on the most recent preclinical and clinical advances in tumor immunology and cancer immunotherapy

For more information, please visit the official Sidra Symposium website at: http://sidrasitcqatar2014.com/.